A Primer in Precision Pathology: Genomics, AI and Immuno-oncology

📅 Tue, March 03  
⏰ 7:45 AM - 4:35 PM
📍 LACC 403 B

生产总: 6.75 • SAM: 6.75

This course is co-sponsored by the Association for Molecular Pathology.

In the era of personalized oncology, the pathologist is now, more than ever, expected to play a central role in the management of cancer patients. Efforts to develop curricula that will address the educational needs in genomics, immunogenomics, and digital pathology for pathologists in
training are being developed by academic institutions and professional organizations. Upon completion of this educational activity, the learner will be able to:

- Discuss the overall principles of massively parallel sequencing (next-generation sequencing) technologies and the challenges and opportunities associated with the incorporation of these tools into the daily practice of the pathologist. Identify specimen requirements for molecular testing of solid tumors and provide criteria for specimen selection highlighting challenges related to use of archival material and formalin fixed paraffin embedded tissue.

- Discuss the genomic landscape and molecular-based classifications of various solid and hematologic cancers (colorectal, lung, gynecologic, breast, and head and neck cancers in addition to soft tissue and bone sarcomas, CNS tumors, lymphoma, and melanoma). Review the clinically relevant genetic alterations in these malignancies and discuss the role of genetic testing in guiding management. Organ-based sessions will be done on a rotational annual basis.

- Review clinical outcomes in solid tumors and hematological malignancies to novel immunotherapies. Discuss histopathological and genetic correlates of clinical response to immunotherapy and describe the development and implementation of novel diagnostic methods to guide immunotherapy.

The course will be useful for practicing pathologists in all settings, pathology residents, oncologic and organ based surgical pathology fellows, and translational scientists interested in focusing their research on developing molecular genetic pathology applications.

**Continuing Medical Education and Continuing Certification**

The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The United States and Canadian Academy of Pathology designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) and Lifelong Learning (Part II) credit for the purpose of meeting the ABPath requirements for Continuing Certification (CC).

Physicians can earn a maximum of 6.75 SAM/Part II credit hours.
Session Chairs

Karen Kaul, MD, PhD, Pathology, NorthShore University HealthSystem

George J. Netto, MD, The University of Alabama at Birmingham

Presentations

7:45 AM  Introduction - Netto
George J. Netto, MD
The University of Alabama at Birmingham

Information regarding this session is limited as it requires a ticket be purchased. Please login to see additional materials.

7:50 AM  Next Generation Sequencing Technology: A Primer to the Anatomic Pathologist

8:30 AM
8:30 AM | Q&A
8:35 AM

8:35 AM | Artificial Intelligence Meets Digital Pathology: Next Generation Morphology Practice
9:15 AM | Liron Pantanowitz, MD
University of Pittsburgh

Information regarding this session is limited as it requires a ticket be purchased. Please login to see additional materials.

9:15 AM | Q&A
9:20 AM

9:20 AM | Update on Biomarkers of Immuno-oncology: PD-L1, TMB, and Beyond
10:05 AM
10:05 AM | Q&A

10:15 AM

10:15 AM | Break: Visit the Posters in the Exhibit Hall

10:45 AM

10:45 AM | Molecular Testing of Solid Tumors: Anatomic Pathologist in Charge of Pre-analytics

Anna Yemelyanova, MD
Pathology
University of Alabama at Birmingham

11:25 AM

Information regarding this session is limited as it requires a ticket be purchased. Please login to see additional materials.

11:25 AM | Q&A

11:30 AM
11:30 AM | Molecular Testing in the Management of Patients with Breast Cancer: Current Status and Future Directions
Stuart J. Schnitt, MD
Dana-Farber/Brigham and Women’s Cancer Center, Harvard Medical School

Information regarding this session is limited as it requires a ticket be purchased. Please login to see additional materials.

12:10 PM | Q&A

12:10 PM | Q&A

12:15 PM | Lunch

12:15 PM | Lunch

1:15 PM | Molecular Markers for Targeted Lung Cancer Therapy
John Lafrate, MD, PhD
Massachusetts General Hospital

Information regarding this session is limited as it requires a ticket be purchased. Please login to see additional materials.

1:55 PM | Q&A

1:55 PM | Q&A
2:00 PM | Interactive Session: Lung Cancer Molecular Tumor Board Case Presentation
John Iafrate, MD, PhD
Massachusetts General Hospital

Information regarding this session is limited as it requires a ticket be purchased. Please login to see additional materials.

2:15 PM | Interactive Session: Lung Cancer Molecular Tumor Board Case Presentation
Ravi Salgia, MD, PhD
City of Hope Medical Center

Information regarding this session is limited as it requires a ticket be purchased. Please login to see additional materials.

2:30 PM | Q&A

2:35 PM | Molecular Advances in Gynecologic Pathology: An Update for the Anatomic Pathologist
Break: Visit the Posters in the Exhibit Hall

3:15 PM to 3:45 PM

GIST and Melanoma: The KIT Connection and So Much More

3:45 PM to 4:25 PM
Alexander J. Lazar, MD, PhD
The University of Texas MD Anderson Cancer Center

Wrap Up and Adjournment - Kaul

4:25 PM to 4:30 PM
Karen L. Kaul, MD, PhD
Pathology
NorthShore University HealthSystem
Please login to see additional materials.